Avalo Therapeutics (AVTX) Debt to Equity (2016 - 2025)
Avalo Therapeutics' Debt to Equity history spans 11 years, with the latest figure at $0.0 for Q2 2025.
- For Q2 2025, Debt to Equity changed N/A year-over-year to $0.0; the TTM value through Jun 2025 reached $0.0, changed N/A, while the annual FY2024 figure was $0.0, N/A changed from the prior year.
- Debt to Equity reached $0.0 in Q2 2025 per AVTX's latest filing, up from $0.0 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $1.42 in Q4 2021 to a low of -$8.14 in Q3 2022.
- Average Debt to Equity over 5 years is -$1.59, with a median of -$0.62 recorded in 2022.
- The largest YoY upside for Debt to Equity was 186.86% in 2022 against a maximum downside of 186.86% in 2022.
- A 5-year view of Debt to Equity shows it stood at $1.42 in 2021, then crashed by 186.86% to -$1.24 in 2022, then crashed by 35.22% to -$1.67 in 2023, then soared by 100.16% to $0.0 in 2024, then soared by 30.75% to $0.0 in 2025.
- Per Business Quant, the three most recent readings for AVTX's Debt to Equity are $0.0 (Q2 2025), $0.0 (Q1 2025), and $0.0 (Q4 2024).